Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service, Webcast

ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer's Disease (CTAD) Meeting on December 4, 2019


ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a treatment for dementia-related psychosis at the upcoming 12th Clinical Trials on Alzheimer's Disease (CTAD) Meeting.

Webcast Details

The live webcast will include a presentation of the results by ACADIA management followed by a KOL panel discussion with live Q&A. The live webcast will be available on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there through January 4, 2020.

About Dementia-Related Psychosis

Around 8 million people in the United States are living with dementia and studies suggest that approximately 30% of dementia patients, or 2.4 million people, have psychosis, commonly consisting of delusions and hallucinations1,2. Dementia-related psychosis includes psychosis in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease dementia, vascular dementia, and frontotemporal dementia. Serious consequences have been associated with severe or persistent psychosis in patients with dementia such as repeated hospital admissions, increased likelihood of nursing home placement, progression of dementia, and increased risk of morbidity and mortality3.

About Pimavanserin

Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in psychosis, schizophrenia, depression and other neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. ACADIA is evaluating pimavanserin in an extensive clinical development program across multiple indications with significant unmet need including dementia-related psychosis, adjunctive major depressive disorder, and the negative symptoms of schizophrenia. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID®. NUPLAZID is not approved for dementia-related psychosis, schizophrenia or major depressive disorder.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia, major depressive disorder, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: the potential benefits of pimavanserin as a treatment for dementia-related psychosis or other central nervous system disorders as well as the potential results of clinical trials of pimavanserin in other indications. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2018 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Important Safety Information and Indication for NUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA RELATED PSYCHOSIS

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

Indication: NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Dosage and Administration: Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please see the full Prescribing Information including Boxed WARNING for NUPLAZID.

References
12017 Alzheimer's Disease Facts and Figures and ACADIA market research
2Plassman BL, et al. Prevalence of dementia in the United States: the Aging Demographics, and Memory study. Neuroepidemiology. 2007;29(1-2):125-132.
3Connors MH et al. Am J Geriatr Psychiatry 2018;26(3). Peters ME et al. Am J Psychiatry 2015;172(5). Haupt M et al. Int J Geriatr Psychiatry 1996;11(11). Naimark D et al. J Am Geriatr Soc 1996;44(3). Stern Y et al. Neurology 1994;44(12).


These press releases may also interest you

at 22:30
Canadian digital healthcare portal Ask The Doctor has launched a toll-free number for anyone around the world to call who are concerned about the Coronavirus. "It is our duty and it is our responsibility to help people around the world as we are...

at 14:05
Accumen Inc., the leader in healthcare performance within ancillary services, today announced that it is partnering with AABB and The Joint Commission to provide a complimentary series of Patient Blood Management (PBM) Certification webinars focusing...

at 11:00
February 17, 2020 The itinerary of events includes: Vancouver, British Columbia 8:00a.m. PST: Minister Hajdu, The Honourable Adrian Dix, British Columbia Minister of Health, and His Worship Kennedy Stewart, Mayor of Vancouver, will host a roundtable...

at 08:00
Chad Price, the CEO of Mako Medical, announced this week that Mako Medical Laboratories is launching a new DNA test focused on Nutrition. "This is a first step in helping people understand exactly what foods they should eat so they can optimize...

at 08:00
In Partnership with the Smiles for Everyone Foundation, Bright Now!® Dental will provide free dental services at its Kennewick, WA office. A limited number of appointments are available, but there is plenty of room for walk-ins if individuals are...

15 fév 2020
Further to my previous statements, as Chief Public Health Officer, I have assessed additional individuals in quarantine at Canadian Forces Base (CFB) Trenton pursuant to an Emergency Order under the Quarantine Act and determined that they do not pose...



News published on 11 november 2019 at 09:05 and distributed by: